Current Oncology Reports Q1 Unclaimed
Current Oncology Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal serves all those involved in the diagnosis, treatment, management, and prevention of cancer. It has an SJR impact factor of 1,498.
Current Oncology Reports focuses its scope in these topics and keywords: cancer, circulating, role, diagnosis, tumor, obesity, transplantation, resistance, primary, patients, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
3190 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
1,498
SJR Impact factor77
H Index132
Total Docs (Last Year)445
Total Docs (3 years)9478
Total Refs2209
Total Cites (3 years)441
Citable Docs (3 years)4.93
Cites/Doc (2 years)71.8
Ref/DocOther journals with similar parameters
Molecular Cancer Q1
Journal of Thoracic Oncology Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1
Compare this journals
Aims and Scope
Best articles by citations
Epidemiology of Brain Metastases
The Obesity Paradox in Cancer: a Review
Obesity and Cancer Risk: Recent Review and Evidence
HIF Inhibitors: Status of Current Clinical Development
The role of C-reactive protein as a prognostic indicator in advanced cancer
The Impact of Obesity on Breast Cancer Diagnosis and Treatment
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Cancer-Promoting Effects of Microbial Dysbiosis
COVID-19 and Cancer: a Comprehensive Review
Perifosine: Update on a novel Akt inhibitor
VEGF Inhibition, Hypertension, and Renal Toxicity
Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Pazopanib: A novel multitargeted tyrosine kinase inhibitor
Changes in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging of Head and Neck Cancer: Rationale and Implications
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
Emerging Variants of Castration-Resistant Prostate Cancer
Clinical and Biological Features of Neuroendocrine Prostate Cancer
Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
Comments